New study tracks TAKHZYRO's safety for swelling disorder over one year
NCT ID NCT05397431
First seen Feb 04, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study monitors 155 people in Japan with hereditary angioedema (HAE) who are taking TAKHZYRO (lanadelumab) for the first time. Researchers will track side effects and how well the drug controls swelling attacks over 12 months. The goal is to confirm the medicine's safety and effectiveness in real-world use, not to cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda selected site
Tokyo, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.